Abstract Body

Background: The mutational profiles selected in vivo by integrase inhibitors (INIs) have been primarily defined within clinical trials that involved predominantly subjects with HIV-1 subtype B infection. CORONET is multicentre surveillance programme that aims to characterise INI-resistance in diverse INI-naïve and INI-experienced European cohorts. This analysis addressed the influence of HIV-1 subtype on pathways of genotypic resistance and cross-resistance observed in raltegravir-experienced patients.

Methods: Integrase sequences produced by Sanger sequencing at 9 clinical centres were analysed centrally to identify major INI resistance-associated mutations (RAMs) as defined by the Stanford interpretation algorithm. Codon usage at major integrase resistance codons was analysed using integrase sequences from INI-naïve patients. Proportions were compared by Fisher’s Exact test (2-sided).

Results: Sequences were examined from 255 raltegravir-experienced (subtype B 209/255, 82%) and 533 raltegravir-naïve patients (subtype B 399/533, 75%). Non-B subtypes comprised 11 different variants: the most prevalent were subtype C and CRF02; other variants included A, D, F, G, CRF01, CRF06 and CRF09. Overall 113 (44%) raltegravir-experienced patients had evidence of ≥1 major INI RAM, predominantly N155H (57, 22%), G140S (33, 13%), Q148H (28, 11%), and Q148R (15, 6%). 36/44 (82%) of patients with mutations Q148H/R/K had co-existing G140A/C/S. G140A/C/S and Q148H/R/K were detected in 36/209 (17%) and 42/209 (21%) subtype B infections, and 1/46 (2%, subtype G) and 2/46 (4% subtype C and G) non-B subtype infections respectively (p=0.005 and p=0.009). As a result, prevalence of predicted cross-resistance to dolutegravir was 42 (20%) vs. 2 (4%) in B vs. non-B subtypes respectively (p=0.009). In INI-naive subtype B sequences, emergence of G140S required a single nucleotide substitution (from GGC or GGT to AGC/AGT). With all the non-B viruses sequences analysed, two substitutions were required to mutate the observed codons (GGA or GGG) to a serine codon.

Conclusions: Sequence differences between HIV-1 subtypes influence the pathways of genotypic resistance to raltegravir and resulting cross-resistance to dolutegravir. Subtype B shows a higher propensity to develop the G140/Q148 pathway compared with predominant non-B subtypes circulating in Europe, which is explained by a different codon usage at the G140 position. These findings carry implications for dolutegravir use in raltegravir- and elvitegravir-experienced subjects.